|Day Low/High||1.40 / 1.44|
|52 Wk Low/High||1.53 / 7.95|
These five stocks could be toxic for your portfolio in the month ahead.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Final Results of 24-Week Open-Label Phase 2 Trial Will be Presented by Professor Zohar Argov, MD, Senior Medical Advisor to BioBlast Pharma
Appoints Industry Veteran, Robert W. Cook, as Chief Financial Officer
BioBlast paints a very optimistic picture of Cabaletta's potential as an effective treatment for OPMD, but the data announced Tuesday are scant, cherry-picked and hardly conclusive.
Conference Call and Webcast, 8:30 a.m. Eastern Time
Conference Call and Webcast on Tuesday, October 27th at 8:30 a.m. Eastern Time
Appoints Former Aptalis and Novartis Executive, Theresa M. Stevens, as Chief Corporate Development Officer
Appoints Former NPS and ViroPharma Executive, Paul Firuta as Chief Commercial Officer